Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-04-23 6:22 pm Sale | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 1,839,138 5.1% | -286,459![]() (-13.48%) | View |
2024-02-14 09:25 am Purchase | 13G | Krystal Biotech Inc. KRYS | Avoro Capital Advisors LLC | 2,565,555 9.1% | 1,155,555![]() (+81.95%) | View |
2024-02-14 09:23 am Purchase | 13G | Apellis Pharmaceuticals Inc. APLS | Avoro Capital Advisors LLC | 13,411,111 9.9% | 2,786,111![]() (+26.22%) | View |
2024-02-14 09:22 am Purchase | 13G | AMICUS THERAPEUTICS INC. FOLD | Avoro Capital Advisors LLC | 27,400,000 9.3% | 600,000![]() (+2.24%) | View |
2024-02-14 09:21 am Purchase | 13G | MADRIGAL PHARMACEUTICALS INC. MDGL | Avoro Capital Advisors LLC | 2,288,888 9.9% | 628,888![]() (+37.88%) | View |
2024-02-14 09:20 am Sale | 13G | Mersana Therapeutics Inc. MRSN | Avoro Capital Advisors LLC | 0 0% | -7,550,000![]() (Position Closed) | View |
2024-02-14 09:18 am Sale | 13G | PMV Pharmaceuticals Inc. PMVP | Avoro Capital Advisors LLC | 0 0% | -3,060,000![]() (Position Closed) | View |
2024-02-14 09:17 am Purchase | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | Avoro Capital Advisors LLC | 3,755,555 6.5% | 655,555![]() (+21.15%) | View |
2024-02-14 09:15 am Sale | 13G | Kymera Therapeutics Inc. KYMR | Avoro Capital Advisors LLC | 3,775,000 6.8% | -75,000![]() (-1.95%) | View |
2024-02-14 09:14 am Purchase | 13G | Monte Rosa Therapeutics Inc. GLUE | Avoro Capital Advisors LLC | 4,535,000 9.1% | 210,000![]() (+4.86%) | View |
2024-02-14 09:13 am Sale | 13G | Mirati Therapeutics Inc. MRTX | Avoro Capital Advisors LLC | 4,886,840 7% | -668,715![]() (-12.04%) | View |
2024-02-14 09:12 am Purchase | 13G | Xenon Pharmaceuticals Inc. XENE | Avoro Capital Advisors LLC | 5,666,666 7.7% | 766,666![]() (+15.65%) | View |
2024-02-14 09:10 am Purchase | 13G | Verrica Pharmaceuticals Inc. VRCA | Avoro Capital Advisors LLC | 6,583,332 9.99% | 6,583,332![]() (New Position) | View |
2024-02-14 09:09 am Purchase | 13G | CYMABAY THERAPEUTICS INC CBAY | Avoro Capital Advisors LLC | 16,337,739 9.99% | 3,537,739![]() (+27.64%) | View |
2024-02-14 09:08 am Purchase | 13G | SPYRE THERAPEUTICS, INC SYRE | Avoro Capital Advisors LLC | 2,125,597 5.9% | 2,125,597![]() (New Position) | View |
2024-02-14 09:07 am Purchase | 13G | Structure Therapeutics Inc. GPCR | Avoro Capital Advisors LLC | 6,999,999 5% | 6,999,999![]() (New Position) | View |
2024-02-14 09:05 am Sale | 13G | UNITED THERAPEUTICS Corp UTHR | Avoro Capital Advisors LLC | 2,858,888 6.1% | -6,112![]() (-0.21%) | View |
2024-02-14 09:04 am Unchanged | 13G | MARINUS PHARMACEUTICALS INC. MRNS | Avoro Capital Advisors LLC | 3,150,000 5.8% | 0 (Unchanged) | View |
2024-02-14 09:02 am Purchase | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Avoro Capital Advisors LLC | 13,050,000 6.4% | 13,050,000![]() (New Position) | View |
2024-02-14 09:00 am Sale | 13G | IO Biotech Inc. IOBT | Avoro Capital Advisors LLC | 0 0% | -2,055,883![]() (Position Closed) | View |